KDR and neoplasm: The synergistic approach of targeting tumor cells and angiogenesis was simultaneously executed by co-immunization studies with an SFV DNA replicon vector carrying 1-4 domains of murine vascular epidermal growth factor receptor-2 (VEGFR2) and IL-12 and another SFV DNA replicon expressing the survivin and β-hCG antigens [32].